CCM
ANTX icon

Coldstream Capital Management’s AN2 Therapeutics ANTX Stock Holding History

Coldstream Capital Management’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-783
Closed -$1.06K – 1230
2025
Q1 		$1.06K Buy
+783
New +$986 ﹤0.01% 3171

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Coldstream Capital Management's ANTX Position: Q2 2025 in Review

Coldstream Capital Management sold out of AN2 Therapeutics (ANTX) in Q2 2025, closing a stake of 783 shares — an estimated $1.06K sold.

Coldstream Capital Management first reported a position in ANTX in Q1 2025 and held it in 1 quarter. The position peaked at $1.06K in Q1 2025. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2025.

  • Coldstream Capital Management reported no remaining AN2 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 783 AN2 Therapeutics shares in Q2 2025, an estimated $1.06K.
  • Coldstream Capital Management first reported a position in AN2 Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's AN2 Therapeutics position peaked at $1.06K in Q1 2025.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.